Beijing Luzhu Biotechnology Co Ltd (2480)

Currency in HKD
23.30
0.00(0.00%)
Closed·
2480 Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
2480 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
23.3024.50
52 wk Range
20.0027.20
Key Statistics
Bid/Ask
23.30 / 24.86
Prev. Close
23.3
Open
24.5
Day's Range
23.3-24.5
52 wk Range
20-27.2
Volume
15K
Average Volume (3m)
74.2K
1-Year Change
4.48%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
2480 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
31.71
Upside
+36.08%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral

Beijing Luzhu Biotechnology Co Ltd Company Profile

Beijing Luzhu Biotechnology Co., Ltd., a biotechnology company, focuses on the research and development, production, and sale of human vaccines and therapeutic biologics to prevent and control infectious diseases, and treat cancer and autoimmune diseases in Mainland China. Its clinical-stage product candidates include LZ901, a recombinant herpes zoster vaccine, which completed Phase III clinical trial; K3, a recombinant human anti-tumor necrosis factor-alpha monoclonal antibody injection product for the treatment of various autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis, that completed Phase I clinical trial; and K193, a bispecific antibody injection to treat B cell leukemia and lymphoma, which is in Phase I clinical trial. The company’s pre-clinical-stage product candidates comprise Recombinant Varicella vaccine for the prevention of varicella in children; Recombinant Syncytial Virus (RSV) vaccine for the indication of RSV-induced lower respiratory tract disease; Recombinant HSV-1 vaccine that targets oral herpes or cold sores; Recombinant HSV-2 vaccine targets genital herpes; K333, a bispecific antibody injection product for the treatment of myeloid leukemia; and K1932 bispecific antibody to treat b cell lymphoma. In addition, it offers immunoreagents, such as Group A meningococcal polysaccharide IgG, Group C meningococcal polysaccharide IgG, Group Y meningococcal polysaccharide IgG, Group W135 meningococcal polysaccharide IgG, and Haemophilus influenzae Type B polysaccharide IgG antibody detection kits. The company was formerly known as Beijing Luzhu Biotech. The company was incorporated in 2001 and is headquartered in Beijing, China.

Employees
159
Market
Hong Kong

Compare 2480 to Peers and Sector

Metrics to compare
2480
Peers
Sector
Relationship
P/E Ratio
−25.2x−12.2x−0.5x
PEG Ratio
−0.750.270.00
Price/Book
5.0x6.8x2.6x
Price / LTM Sales
-21.9x3.3x
Upside (Analyst Target)
36.1%10.1%43.4%
Fair Value Upside
Unlock−14.2%7.1%Unlock

Analyst Ratings

3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 31.71
(+36.08% Upside)

Earnings

Latest Release
Apr 16, 2025
EPS / Forecast
-0.29 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

2480 Income Statement

FAQ

What Stock Exchange Does Beijing Luzhu Biotechnology Trade On?

Beijing Luzhu Biotechnology is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for Beijing Luzhu Biotechnology?

The stock symbol for Beijing Luzhu Biotechnology is "2480."

What Is the Beijing Luzhu Biotechnology Market Cap?

As of today, Beijing Luzhu Biotechnology market cap is 4.63B.

What Is Beijing Luzhu Biotechnology's Earnings Per Share (TTM)?

The Beijing Luzhu Biotechnology EPS (TTM) is -0.83.

From a Technical Analysis Perspective, Is 2480 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Beijing Luzhu Biotechnology Stock Split?

Beijing Luzhu Biotechnology has split 0 times.

How Many Employees Does Beijing Luzhu Biotechnology Have?

Beijing Luzhu Biotechnology has 159 employees.

What is the current trading status of Beijing Luzhu Biotechnology (2480)?

As of 10 Aug 2025, Beijing Luzhu Biotechnology (2480) is trading at a price of 23.30, with a previous close of 23.30. The stock has fluctuated within a day range of 23.30 to 24.50, while its 52-week range spans from 20.00 to 27.20.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.